Individuals with psychotic disorders have a 10 to 15 year shorter life span compared with the general population, mostly due to physical conditions like obesity, cardiovascular disease, and type 2 diabetes. A cardiometabolic risk prediction algorithm can offer informed treatment decisions in order to prevent long-term cardiometabolic outcomes.
There are disparities in health and health care between hospitalized COVID-19 patients with schizophrenia and without severe mental illness.
The researchers’ goal was to explore the efficacy of cognitive-behavioral therapy for psychosis in patients with a high clinical risk for psychosis.
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
The goal of the researchers was to describe the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) “Marder factors.”
Individuals with schizophrenia are undervaccinated against COVID-19 compared with age- and gender-matched controls in Israel.
The designation is based on results from a phase 2 trial that evaluated the efficacy and safety of 4 different doses of BI 425809 orally once daily in adults with CIAS for 12 weeks.
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
The researchers looked at the effectiveness of cognitive remediation on cognition and functioning in people diagnosed with schizophrenia.
Researchers evaluated a case study and treatment of a patient who was diagnosed with schizophreniform disorder who presented at an emergency department testing positive for COVID-19.